Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxycycline pre-exposure vs post-exposure prophylaxis for STIs
jRCTs031240520Recruiting
- Sponsor
- Japan Institute for Health Security
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of doxycycline in sexually transmitted disease (STD), Chlamydia trachomatis infection, gonorrhea and 2 more (2 arms), sponsored by Japan Institute for Health Security. Primary endpoint: First STI occurrence (composite). Started Dec 2024; status: recruiting.
02
Drugs
doxycycline
03
Conditions
sexually transmitted disease (STD)Chlamydia trachomatis infectiongonorrheasyphilisMycoplasma genitalium infection (Mgen)
Beyond the preview
Go deeper on jRCTs031240520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240520.